Patients experiencing typical symptoms of late-infantile neuronal ceroid lipofuscinoses (LINCL) should be tested for the presence of genetic defects in CLN5 and CLN8, a study says. The findings of the study, “The Neuronal Ceroid Lipofuscinoses-Linked Loss of Function CLN5 and CLN8 Variants Disrupt Normal Lysosomal Function,” were published…
News
With an estimated 1.37 billion inhabitants, India will likely surpass China in five years as the world’s most populous country. That also means it will have more rare-disease patients than any nation. It already has more than twice as many as the 28-member European Union. Harsha K. Rajasimha, a genomics…
Scientists have discovered a new mutation in the CLN3 gene associated with Juvenile Batten disease. The study, “A novel in-frame mutation in CLN3 leads to Juvenile neuronal ceroid lipofuscinosis in a large Pakistani family,” was published in the International Journal of Neuroscience. Neuronal ceroid lipofuscinoses…
Brineura Over 3 Years Seen to Delay Loss of Motor-Language Skills in CLN2 Children, Trial Data Shows
Three years of treatment with Brineura (cerliponase alfa) was seen to effectively and durably delay the progression of late infantile Batten disease, compared to its natural course, in an ongoing and long-term extension study, BioMarin announced. These new results — focused on motor and language skills — demonstrate that Brineura, the first…
Substantial progress has been made by different academic and industry teams toward the development of effective therapies to treat Batten disease, a review study suggests. In addition, many of the research strategies being explored for one form of Batten might be useful for other Batten types and even other disorders. The…
High levels of a protein associated with Parkinson’s disease, called alpha-synuclein, may contribute to the progression of late infantile Batten disease, according to a recent study. The study, “Autophagy–lysosome pathway alterations and alpha-synuclein up-regulation in the subtype of neuronal ceroid lipofuscinosis, CLN5 disease,” was published in…
Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bathdissertation, she analyzed Brexit’s long-term impact…
With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,” warned Avraham Steinberg,…
To advance its commitment to research aimed at improving the lives of those with rare metabolic disorders such as Batten disease, Amicus Therapeutics is establishing a Global Research and Gene Therapy Center of Excellence in Philadelphia, Pennsylvania. The 75,000-square-foot center, scheduled to open this year, will be in…
Rare diseases affect about 30 million Americans — roughly the same number as those with type 2 diabetes. Yet only 5 percent of the estimated 7,000 rare diseases known to science have cures or treatments approved by the U.S. Food and Drug Administration (FDA). Raising awareness of those illnesses and highlighting…
Recent Posts
- FDA clears late infantile Batten disease gene therapy for testing
- Giving thanks for every milestone as a CLN2 Batten disease parent
- Brain abnormalities can vary by age, sex in juvenile Batten
- How Batten disease parents can drive change through advocacy
- How we celebrate Halloween with medically complex children
- Signs of early brain disruption prompt timely CLN3 gene therapy
- Changing seasons brings precious moments of beauty
- Biotech companies partner on Batten disease gene therapy
- No days off: Living in the fire as a rare disease parent
- Personalized gene therapy benefits twins with juvenile Batten disease